18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
Larson
Steven M
SM
Memorial Sloan-Kettering Cancer Center New York, New York, USA. larsons@mskcc.org
Schwartz
Lawrence H
LH
D014408:Biomarkers, Tumor / Q000032:analysis; D019788:Fluorodeoxyglucose F18; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D049268:Positron-Emission Tomography / Q000379:methods* / Q000592:standards*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000592:standards; D011379:Prognosis; D019275:Radiopharmaceuticals; D016896:Treatment Outcome; D014481:United States
D014408:Biomarkers, Tumor; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18